A new antithrombogenic RV-PA valved conduit

Area of Science:

• Biomaterials Engineering
• Cardiovascular Surgery
• Vascular Tissue Engineering

Background:

• Traditional glutaraldehyde-fixed conduits can cause calcification and thrombosis.
• Developing antithrombogenic valved conduits is crucial for right ventricular-pulmonary artery reconstruction.

Purpose of the Study:

• To develop and evaluate a new antithrombogenic right ventricular-pulmonary artery valved conduit using bovine jugular vein.
• To assess the biocompatibility, antithrombogenicity, and healing of the novel conduit in a canine model.

Main Methods:

• A bovine jugular vein was cross-linked with glycerol polyglycidyl ether polyepoxy compound (PC) and surface-heparinized.
• Conduits (18-20 mm ID) were implanted between the right ventricle and pulmonary artery in nine dogs.
• Grafts were explanted and analyzed macroscopically and microscopically at various time points (182-385 days).

Main Results:

• The PC-cross-linked, heparin-bonded conduits exhibited excellent handling and anastomosis without immediate leakage.
• Explants showed smooth luminal surfaces, good cusp coaptation, and minimal calcification or degeneration.
• Small thrombi were observed near cusps, but significant antithrombogenicity was noted, with endothelium-like cells appearing by 196 days.

Conclusions:

• The novel bovine jugular vein valved conduit demonstrates good short-term antithrombogenicity and biocompatibility in a canine RV-PA model.
• Temporary heparin release followed by endothelialization contributes to graft patency in this low-pressure system.
• This approach offers a promising alternative for RV-PA reconstruction, potentially reducing thrombotic complications.